Condiciones de salud que Boswellia puede ayudar a apoyar.
Clinical evidence from IBS and inflammatory bowel disease trials demonstrates that Boswellia significantly reduces recurrent abdominal pain, cramping, and altered bowel movements. At 6-month follow-up, IBS patients given Boswellia scored significantly lower on all IBS symptom measures versus standard management.
Boswellia inhibits the 5-lipoxygenase (5-LOX) enzyme, reducing leukotriene biosynthesis—a key driver of respiratory inflammation. A double-blind, placebo-controlled trial in 40 asthma patients showed 70% improvement in pulmonary function with Boswellia gum resin vs. 27% with placebo. A second trial using a Boswellia/Aegle marmelos combination reduced asthma symptom scores and serum IL-4.
Boswellia serrata extracts demonstrate antioxidant activity correlated with AKBA content, including Nrf2/HO-1 pathway activation, ROS scavenging, and reduction of oxidative stress markers. These effects have been demonstrated in cell studies, ex vivo human immune samples, and clinical contexts including TBI and IBS.
Boswellia serrata resin extracts, standardized to boswellic acids, have been evaluated in multiple randomized controlled trials and a systematic meta-analysis for osteoarthritis and rheumatoid arthritis. The active constituent AKBA inhibits 5-lipoxygenase (5-LOX), suppressing leukotriene-mediated inflammation. A 2020 meta-analysis of seven RCTs (545 patients) found significant improvements in pain and joint function in knee OA.
Boswellia serrata resin and its boswellic acids have shown anti-asthmatic effects by inhibiting 5-lipoxygenase, reducing leukotriene synthesis and Th2 inflammatory responses. A double-blind, placebo-controlled clinical study of 80 asthma patients found 300 mg three times daily for six weeks significantly reduced asthma attack frequency and improved breathing capacity.
Boswellic acids from Boswellia serrata inhibit 5-lipoxygenase, reducing leukotrienes and modulating cytokines relevant to autoimmune inflammation. Pilot clinical studies suggest efficacy in rheumatoid arthritis, Crohn's disease, ulcerative colitis, and multiple sclerosis. Ex vivo research shows Boswellia extracts influence regulatory and effector T-cell compartments.
Boswellia serrata, the Indian frankincense tree, has substantial clinical evidence for musculoskeletal pain including low back pain. A 2020 systematic review and meta-analysis (7 RCTs, 545 patients) found Boswellia significantly reduced pain and improved joint function versus controls. A randomized, double-blind, placebo-controlled trial confirmed efficacy of a Boswellia-turmeric combination for chronic low back pain over 90 days.
Boswellia (Boswellia serrata) has clinical evidence specifically for bronchial asthma. A double-blind, placebo-controlled clinical trial published in the European Respiratory Journal found that 300 mg three times daily of Boswellia extract for 6 weeks significantly improved peak expiratory flow rate and reduced asthma symptoms and exacerbations compared to placebo. Its active boswellic acids inhibit 5-lipoxygenase, a key enzyme in leukotriene-driven bronchial inflammation.
Boswellia (Boswellia serrata, Indian frankincense) has demonstrated anti-inflammatory efficacy in respiratory inflammatory conditions including chronic bronchitis and asthma. A placebo-controlled RCT (40 asthmatic patients, 300 mg three times daily for 6 weeks) showed significant improvement in FEV1, PEF, and attack frequency. Its boswellic acids inhibit 5-lipoxygenase, reducing LTB4, a key mediator of bronchial inflammation.
Boswellia serrata resin contains boswellic acids, especially AKBA, which potently inhibit 5-lipoxygenase, a key inflammatory enzyme in joint disease. A 2020 systematic review and meta-analysis of 7 RCTs (545 patients) found Boswellia significantly reduced osteoarthritis pain, stiffness, and physical function scores vs. control. Podiatric specialists recommend Boswellia as part of a joint inflammation supplement protocol for bunion pain.
Boswellia serrata is explicitly listed by the Arthritis Foundation and ADAM for bursitis. Its boswellic acids (especially AKBA) potently inhibit 5-lipoxygenase, reducing leukotriene-driven joint inflammation. A 2014 Cochrane Review found 100 mg/day enriched AKBA Boswellia reduced OA pain by ~20 points. Traditional Ayurvedic use for joint conditions spans millennia.
Boswellia serrata gum resin contains boswellic acids that inhibit 5-lipoxygenase and NF-κB pathways central to cartilage inflammation and matrix degradation. A 2025 randomized, double-blind, multicenter, placebo-controlled trial in 62 knee OA patients showed Boswellia serrata extract significantly reduced pain, stiffness, cartilage degeneration biomarkers (CTX-II, COMP, MMP-3), and inflammatory markers over 90 days. Multiple systematic reviews and a 2022 network meta-analysis support Boswellia among leading OA nutraceuticals.
Boswellia (Boswellia serrata) has well-documented clinical evidence for addressing chronic inflammation. Its active constituents—particularly 3-acetyl-11-keto-β-boswellic acid (AKBA)—inhibit key pro-inflammatory enzymes and cytokines. Multiple randomized, double-blind, placebo-controlled trials have demonstrated significant reductions in inflammatory biomarkers and symptom improvement across several chronic inflammatory conditions. Evidence strength is moderate overall, as most trials are small and of variable quality.
Boswellic acids from Boswellia serrata inhibit 5-lipoxygenase (5-LOX), reducing leukotriene-driven inflammation. Multiple randomized controlled trials and a 2014 Cochrane review found modest but meaningful benefits for osteoarthritis and chronic inflammatory pain. Ayurvedic medicine has used this resin for centuries to treat inflammatory conditions.
Multiple pilot RCTs show Boswellia extracts can mitigate cognitive decline in aging and neurological injury contexts. Neuroprotective mechanisms include anti-neuroinflammatory activity, antioxidant Nrf2 activation, BDNF upregulation, and possible AChE inhibition. Effects are modest but replicated across several small trials.
Boswellia serrata gum resin extract has been tested in small clinical trials for ulcerative colitis and collagenous colitis. In one study of 20 UC patients receiving 300 mg three times daily for 6 weeks, 14 achieved remission, compared to only 4/10 in the sulfasalazine group. Boswellic acids inhibit 5-lipoxygenase, reducing leukotriene synthesis.
Boswellia serrata (Indian frankincense) resin extracts, particularly boswellic acids, inhibit 5-lipoxygenase (5-LOX) and leukotriene synthesis, reducing inflammatory infiltration in connective tissues including tendons and cartilage. Clinical trials show reduced pain and improved joint function in OA. A 60-day study found oral Boswellia combined with hyaluronic acid significantly improved knee OA outcomes.
Boswellia (Boswellia serrata) resin contains boswellic acids that reduce intestinal inflammation by inhibiting 5-lipoxygenase. It is identified in double-blind RCTs specifically for Crohn's disease, showing comparable efficacy to mesalamine for active CD in one trial. A larger maintenance trial found it safe but not superior to placebo for remission maintenance.
Boswellia (olibanum/frankincense) resin has clinical evidence for inflammatory dermatoses. A 200-patient study for psoriasis-related dermatitis found significant PASI reduction with an AKBA-containing ointment. Traditional use in Greco-Roman medicine for skin disorders is well-documented. Anti-inflammatory mechanisms center on 5-lipoxygenase and NF-κB inhibition.
Boswellia serrata was specifically combined with curcumin in a 30-day clinical study in SUDD patients demonstrating significant gastric pain reduction. Multiple authoritative diverticulitis management resources identify Boswellia for its gastrointestinal anti-inflammatory properties via 5-lipoxygenase inhibition, making it mechanistically well-suited for diverticular inflammation.
Boswellia serrata (Indian frankincense) is an Ayurvedic herb whose active boswellic acids, particularly AKBA, selectively inhibit 5-lipoxygenase and leukotriene synthesis, reducing joint inflammation. A 2020 meta-analysis of seven RCTs (545 patients) showed Boswellia significantly reduced OA pain, stiffness, and physical function scores. A 2025 network meta-analysis of 4,599 KOA patients ranked Boswellia as having the highest probability of being most effective for pain and stiffness.
Boswellia serrata (Indian frankincense) contains boswellic acids that specifically inhibit 5-lipoxygenase (5-LOX), a key driver of chronic inflammation underlying aging. Multiple RCTs demonstrate Boswellia extract reduces joint pain and inflammation in osteoarthritis (an age-related condition) with fewer side effects than NSAIDs. Anti-inflammatory activity is highly relevant to healthy aging.
Boswellia serrata oleoresin was evaluated alongside ginger in a 2019 randomized, double-blind, placebo-controlled clinical trial (Eshaghian et al., Complement Ther Med) involving 102 women with heavy menstrual bleeding. Both frankincense and ginger, taken as adjuncts to ibuprofen, significantly reduced bleeding amount and duration and improved quality of life compared to ibuprofen plus placebo. Boswellic acids are thought to inhibit leukotriene and prostaglandin synthesis, reducing uterine inflammation.
Boswellia serrata gum resin has been evaluated in multiple small RCTs for IBD, showing efficacy in ulcerative colitis and Crohn's disease comparable in some trials to mesalazine. Its active boswellic acids inhibit 5-lipoxygenase and leukotriene synthesis, key inflammatory pathways in IBD. It has traditional use in Ayurvedic medicine for inflammatory gut conditions.
In vitro studies show Boswellia serrata extract and AKBA preserve intestinal tight-junction proteins (ZO-1, occludin), maintain transepithelial resistance, and prevent NF-κB-driven barrier disruption in colonic epithelial monolayers. This mechanism supports a role in protecting intestinal barrier integrity.
Boswellia serrata (Indian Frankincense) has traditional Ayurvedic use for respiratory conditions and is supported by modern evidence in asthma. Clinical trials have shown boswellic acids reduce asthma symptoms and improve FEV1 through 5-lipoxygenase inhibition and reduction of leukotriene-mediated airway inflammation.
Boswellia serrata resin extract demonstrated dose-dependent mast cell stabilizing activity in compound 48/80-induced degranulation models in rats (PubMed 15320503). Its boswellic acids inhibit 5-LOX, suppress NF-κB, inhibit histamine release, and human mast cell pharmacological studies report up to 71% inhibition of histamine release. Boswellia is used in Ayurvedic medicine for allergy and asthma.
Human RCTs show Boswellia-containing formulas improve memory and cognitive function. A double-blind RCT in 70 older adults found a B. serrata/Melissa officinalis combination improved memory after one month. A separate placebo-controlled trial in TBI patients (n=80) demonstrated significant improvement in RAVLT, DSST, and TMT-B scores with a boswellic acid formula.
A 2023 double-blind RCT demonstrated a turmeric–boswellia–sesame formulation provided 12.6 times greater total pain relief than placebo in primary dysmenorrhea. Boswellic acids inhibit 5-lipoxygenase (5-LOX), reducing leukotriene-driven uterine inflammation. Boswellia has traditional Ayurvedic use for gynecological complaints.
Boswellia serrata extract is supported by a 2025 RCT (n=50) specifically for DOMS, where 60 mg/day for 10 days significantly attenuated muscle and joint soreness after downhill running vs. placebo. Boswellic acids inhibit 5-lipoxygenase. Traditional use in Ayurveda for musculoskeletal pain preceded modern research.
A prospective clinical study found a combination formula including Boswellia serrata effective for improving symptoms of chemotherapy-induced peripheral neuropathy with no significant toxicity. Mechanistic rationale involves anti-neuroinflammatory and antioxidant properties of boswellic acids.
Boswellia serrata resin contains boswellic acids that inhibit 5-lipoxygenase, reducing leukotriene synthesis — a key mediator of nasal mucosal inflammation and mucus hypersecretion in rhinitis. Clinical evidence supports its use in perennial allergic rhinitis and chronic sinusitis. A 2023 randomized case-control study (PMC10142908) found a supplement containing Boswellia significantly reduced rhinorrhea and nasal hyperemia in chronic sinusitis patients versus steroid-alone control.
Boswellia serrata resin extract demonstrates anti-inflammatory and analgesic properties via 5-LOX inhibition relevant to post-surgical recovery. A 2025 breast cancer surgery RCT found a Boswellia phytosome-containing supplement significantly reduced post-operative oedema, and orthopaedic post-surgical nutrition reviews identify Boswellia as a clinically supported NSAID-sparing agent.
Boswellia (Boswellia serrata), also known as Indian Frankincense, contains boswellic acids with potent anti-inflammatory activity via 5-LOX inhibition. It is included in post-viral recovery anti-inflammatory protocols. A post-viral recovery clinical protocol (Holistic Primary Care, 2023) includes Boswellia/Frankincense as part of an herbal anti-inflammatory combination for COVID recovery.
Boswellia (frankincense) extracts have been studied for psoriasis based on their boswellic acid content, which inhibits 5-lipoxygenase. A clinical study of 200 patients with mild-to-moderate psoriasis using a 5% AKBA ointment three times daily for 12 weeks showed significant reductions in PASI and inflammatory biomarkers including LTB4, TNF, VEGF, and PGE2.
Boswellic acids, especially AKBA, inhibit 5-lipoxygenase (5-LOX), reducing inflammatory leukotrienes that attack joints. Multiple RCTs and a 2014 Cochrane Review support its use for inflammatory joint conditions including RA, reducing pain and improving joint function. Used in Ayurveda for centuries for inflammatory diseases.
Boswellia serrata resin contains boswellic acids that inhibit 5-lipoxygenase, reducing leukotriene-mediated inflammation relevant to nerve root irritation in sciatica. A 2025 prospective multicenter observational study of Boswellia serrata as add-on therapy in 103 chronic low-back and neuropathic pain patients showed significant reductions in pain scores. A double-blind placebo-controlled trial of a Boswellia-turmeric combination significantly reduced chronic lower back pain.
A randomized controlled trial tested a Boswellia serrata and bromelain compound in 150 patients with seasonal allergic rhinitis (SAR) complicated by recurrent respiratory infections, finding large clinical benefit. The compound's anti-5-LOX and anti-thromboxane actions provide the mechanistic rationale.
Boswellic acids from Boswellia serrata inhibit 5-LOX and NF-κB, reducing sinus mucosal inflammation. A 2023 case-control study (MDPI) evaluated an oral supplement containing Boswellia serrata plus bromelain for chronic sinusitis, finding improvements in nasal findings and inflammatory markers. Traditional use in Ayurvedic medicine for respiratory inflammation is established.
Boswellia serrata was used as a key ingredient in a clinical RCT nutraceutical formulation specifically for TMD patients, showing significant pain reduction over 40 days. Boswellic acids inhibit 5-lipoxygenase and reduce pro-inflammatory leukotriene synthesis. It has been cited alongside glucosamine and palmitoylethanolamide in TMD nutraceutical research reviews.
Boswellia (frankincense) resin and its boswellic acids have documented anti-inflammatory wound-healing properties via inhibition of 5-lipoxygenase. Topical Boswellia-containing formulations have been tested in preclinical wound-healing models with positive outcomes, and traditional use for wounds spans millennia.
Ayurvedic texts list Boswellia (Shallaki) as indicated for diarrhea (Atisara) and dysentery. Traditional preparations used bark decoction or gum resin internally. No rigorous human RCT has evaluated Boswellia specifically for acute diarrhea as an isolated endpoint.
Classical Ayurvedic texts list Boswellia resin as indicated for Jwara (fever). This represents traditional use without corroborating human clinical trial evidence for antipyretic activity.
Boswellia (Indian frankincense) contains boswellic acids that inhibit 5-lipoxygenase, suppressing leukotriene-mediated inflammation central to gout flares. Boswellia dalziellii extracts demonstrated 5-LO inhibitory activity in the PMC 2022 review of anti-inflammatory compounds in gout. Ayurvedic and African traditional medicine have used Boswellia for arthritis and gout for centuries.
Ayurvedic texts list Boswellia (Shallaki) as indicated for Arsha (hemorrhoids). The anti-inflammatory and astringent properties of the resin support this traditional use, but no human clinical trials have evaluated Boswellia specifically for hemorrhoids.
Boswellia serrata has traditional Ayurvedic use for GI inflammatory complaints and clinical evidence from IBD trials (comparable to mesalazine for ulcerative colitis) supporting GI anti-inflammatory application. For IBS, evidence is primarily mechanistic (5-LOX inhibition, mast cell stabilization relevant to IBS pathophysiology) and from traditional Ayurvedic use, with extrapolation from IBD trials. IBS-specific standalone RCTs are limited.
Preclinical animal evidence shows Boswellia serrata extract protects nigrostriatal dopaminergic neurons and improves motor impairments in a 6-OHDA rat model of Parkinson's disease. No human clinical trial has been conducted in Parkinson's patients. Traditional Ayurvedic texts also list psychological and movement-disorder applications.
Boswellia (Indian frankincense) is cited in rosacea naturopathic literature as a potent anti-inflammatory for skin inflammation, with boswellic acids specifically inhibiting 5-lipoxygenase (leukotriene B4 synthesis). Used traditionally in Ayurvedic medicine for inflammatory skin conditions. Clinical evidence specific to rosacea is lacking; primary support is traditional use and mechanistic rationale.
Boswellia (frankincense, Boswellia serrata/sacra) has documented anti-inflammatory and immunomodulatory properties mediated by boswellic acids, particularly AKBA. Traditional use in Ayurvedic and Middle Eastern medicine for infectious and inflammatory diseases spans millennia. Modern evidence suggests modulation of inflammatory pathways relevant to viral immune response, though direct antiviral clinical RCTs are limited.
Volver